{"id":305059,"date":"2024-09-16T00:00:00","date_gmt":"2024-09-16T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0008-2024-biopharma-alopecia-landscape-forecast-niche-rare-disease-landscape-forecast\/"},"modified":"2026-04-24T11:17:14","modified_gmt":"2026-04-24T11:17:14","slug":"nrlfim0008-2024-biopharma-alopecia-landscape-forecast-niche-rare-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0008-2024-biopharma-alopecia-landscape-forecast-niche-rare-disease-landscape-forecast\/","title":{"rendered":"Alopecia &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Alopecia areata (<abbr title=\"alopecia areata\">AA<\/abbr>) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary goal of treatment is to stimulate hair growth by alleviating the inflammation at sites of hair loss. Topical \/ intralesional corticosteroids and topical immunotherapy are commonly prescribed for <abbr title=\"alopecia areata\">AA<\/abbr>. Since 2022, the <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> and <abbr title=\"European Commission\">EC<\/abbr> have approved the <abbr data-abbreviation-entity=\"7988\" title=\"Janus-activated kinase\">JAK<\/abbr> inhibitors baricitinib (Eli Lilly) and ritlecitinib (Pfizer) for severe <abbr data-abbreviation-entity=\"8664\" title=\"alopecia areata\">AA<\/abbr>. In July 2024, the <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr> approved a third <abbr data-abbreviation-entity=\"7988\" title=\"Janus-activated kinase\">JAK<\/abbr> inhibitor for <abbr title=\"alopecia areata\">AA<\/abbr>: Sun Pharma\u2019s deuruxolitinib. The late-phase pipeline for this indication is small, consisting of an investigational <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitor and a novel botanical drug. In this report, we provide an analysis of <abbr title=\"alopecia areata\">AA<\/abbr> epidemiology, current disease management, unmet needs, and the clinical and commercial potential of emerging therapies for the disease.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is the diagnosed <abbr title=\"alopecia areata\">AA<\/abbr> population, and how will its size change between 2023 and 2033? How large are the diagnosed alopecia totalis and universalis populations?<\/li>\n<li>What are the key unmet clinical needs in <abbr title=\"alopecia areata\">AA<\/abbr> and to what degree will they be fulfilled by 2033?<\/li>\n<li>What is the current state of treatment in <abbr title=\"alopecia areata\">AA<\/abbr>, and how will it evolve over time?<\/li>\n<li>What emerging <abbr title=\"alopecia areata\">AA<\/abbr> therapies are viewed by treating dermatologists as most promising, and what sales \/ uptake will they achieve in <abbr title=\"alopecia areata\">AA<\/abbr>? How will newer-to-market and emerging <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors fit into the <abbr title=\"alopecia areata\">AA<\/abbr> treatment algorithm?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Niche &#038; Rare Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p><em>Niche &#038; Rare Disease Landscape &#038; Forecast<\/em> features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n<p><strong>Geography:<\/strong> United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>.<\/p>\n<p><strong>Primary research:<\/strong> Six country-specific interviews with thought-leading dermatologists and supported by survey data collected for this study.<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incident cases, diagnosed incident cases by severity, diagnosed lifetime prevalent cases, and drug-treated prevalence by country.<\/p>\n<p><strong>Forecast:<\/strong> Drug-level sales and patient share of key <abbr title=\"alopecia areata\">AA<\/abbr> therapies through 2033.<\/p>\n<p><strong>Emerging therapies:<\/strong> Coverage of key current and emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-305059","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":9,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305059\/revisions"}],"predecessor-version":[{"id":575909,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305059\/revisions\/575909"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}